Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis
British Journal of Haematology · 2023-08 · 202 (3) · 690-692
DOI: 10.1111/bjh.18886 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Haematology, online erschienen am 24.05.2023. Verfasst von Dana Audrey Lawrie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Haematology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Dana Audrey Lawrie, Dennis Lund Hansen, Henrik Frederiksen
Zitieren
APA
Lawrie, D. A., Mannering, N., Hansen, D. L., & Frederiksen, H. (2023). Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis. British Journal of Haematology, 202(3), 690-692. https://doi.org/10.1111/bjh.18886
Vancouver
Lawrie DA, Mannering N, Hansen DL, Frederiksen H. Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis. British Journal of Haematology. 2023;202(3):690-692. doi:10.1111/bjh.18886
BibTeX
@article{Lawrie2023,
author = {Lawrie, Dana Audrey and Mannering, Nikolaj and Hansen, Dennis Lund and Frederiksen, Henrik},
title = {Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis},
journal = {British Journal of Haematology},
year = {2023},
volume = {202},
number = {3},
pages = {690--692},
doi = {10.1111/bjh.18886}
}
EUVIMED